ClinicaliQ Trial Snapshot
- A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) — Active Not Recruiting • Phase II • NCT05490446.
- A trial testing whether tebapivat reduces blood transfusion needs in patients with low-risk bone marrow disorders.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participants with LR-MDS in phase 2b. Conditions: Myelodysplastic Syndromes Interventions: Tebapivat Lead Sponsor: Agios Pharmaceuticals, Inc. Planned Enrollment: 87 participants